Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited
Your view on BOT.AX
Overview
What the company does, where it operates, and who runs it.
About Botanix Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections.
Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis.
Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Botanix Pharmaceuticals Limited. Starting points for Botanix Pharmaceuticals Limited: EPS -AUD 0.03, beta 0.86 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Botanix Pharmaceuticals Limited. Trailing twelve-month EPS for Botanix Pharmaceuticals Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.01 | −AUD 0.00 |
| Lowest estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.02 | −AUD 0.00 |
| Highest estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.00 | −AUD 0.00 |
| Number of analysts | 1 | 1 | 2 | 2 |
| A year ago | −AUD 0.021 | −AUD 0.031 | −AUD 0.031 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 22.50M | AUD 25.60M | AUD 56.07M | AUD 104.53M |
| Lowest estimate | AUD 22.50M | AUD 25.60M | AUD 44.30M | AUD 61.10M |
| Highest estimate | AUD 22.50M | AUD 25.60M | AUD 74.60M | AUD 140.50M |
| Number of analysts | 1 | 1 | 3 | 3 |
| A year ago | AUD 377597.00 | AUD 5.41M | AUD 34.51M | — |
| Growth vs a year ago | +5858.7% | +373.1% | +62.5% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| ARX.AXAroa Biosurgery Limited | Healthcare | Medical - Devices | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| AVR.AXAnteris Technologies Ltd | Healthcare | Medical - Devices | — | ||
| DXB.AXDimerix Limited | Healthcare | Biotechnology | — | ||
| MVF.AXMonash IVF Group Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| NYR.AXNyrada Inc. | Healthcare | Biotechnology | — | ||
| OCC.AXOrthocell Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| PYC.AXPYC Therapeutics Limited | Healthcare | ASX | — | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Botanix Pharmaceuticals Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Botanix Pharmaceuticals Limited. Coverage tracks Botanix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Botanix Pharmaceuticals Limited.